Set against the compounds it is usually grouped with, Dihexa is by a wide margin the least studied in people: the entire case for it rests on cell culture and rodent work, and the two papers that built that case have since been flagged, one carrying a 2021 notice of concern and one retracted in 2025. The neurotrophic peptides it gets listed beside, Cerebrolysin, Semax, Selank and Noopept, are each registered as a medicine in at least one country and carry published human trials, however uneven that literature is, and the classic nootropic classes carry decades of documented human exposure. Dihexa is neither a medicine nor a supplement in any jurisdiction and circulates only as a research chemical of uncertain purity.
Dihexa has no completed published human trial, no approved indication in any country and no established human dose, half-life or safety profile, while the neurotrophic peptides and classic nootropic classes it is compared against carry at least some randomized human data and, in several cases, marketing authorization.
The separation is categorical rather than a matter of degree. Nearly everything marketed for cognition acts on signal traffic that already exists, supplying choline, slowing acetylcholine breakdown, modulating glutamatergic transmission or shifting catecholamine tone, which changes how loudly an existing circuit speaks. Dihexa was described instead as strengthening a growth-factor pathway associated with building new connections, and that description now sits on retracted ground, which matters to anyone weighing the comparison honestly.
The hepatocyte growth factor and c-Met account of Dihexa's action rests on a single 2014 paper that the journal retracted in 2025, and no human pharmacodynamic data confirms that the pathway is engaged in a living human brain at any tolerated dose.
The family tree explains most of what is distinctive here. Angiotensin IV improved rodent performance on memory tasks when infused directly into the brain from the late 1980s onward, but a bare six amino acid peptide is cleared by peptidases within minutes and does not meaningfully cross the blood-brain barrier. Two decades of medicinal chemistry followed, aimed squarely at that delivery problem rather than at the pharmacology.
The two six-carbon lipophilic caps that shield Dihexa from aminopeptidase and carboxypeptidase attack also leave only the pharmacophore of angiotensin IV intact, and published rodent work has not reported the blood-pressure effects expected of a conventional angiotensin receptor agonist.
These are the closest comparators in concept and the furthest apart in evidence. Cerebrolysin is not a single molecule but a standardized enzymatic breakdown product of porcine brain tissue, and its Cochrane reviews are no endorsement: the acute ischaemic stroke review found on moderate-quality evidence probably little or no effect on preventing death, alongside a potential increase in non-fatal serious adverse events, while the vascular dementia review rested on six trials in 597 participants rated very low quality. Thin evidence is still a different object from no evidence, and that is the gap the comparison turns on.
| Compound | Registration | Published human trial data |
|---|---|---|
| Cerebrolysin | Marketed for decades in parts of Europe, Asia and Latin America; not the United States | Multiple randomized trials, Cochrane reviews |
| Semax | Registered as a medicine in Russia | Mostly small, Russian-language studies |
| Selank | Registered as a medicine in Russia | Mostly small, Russian-language studies |
| Noopept | Registered in Russia and some neighboring states | Limited, largely Russian-language |
| Dihexa | No approval in any country | None published |
Cerebrolysin, Semax, Selank and Noopept each hold registration as a medicine in at least one country, a defined dosage form and an adverse event record a clinician can consult, while Dihexa targets a different pathway, the hepatocyte growth factor and c-Met axis, and holds none of those three things.
Comparing across these classes is mostly an exercise in noticing that they answer different questions. The established classes act on transmission, take effect within hours and wash out on discontinuation, which is what allows their effects to be measured and their doses to be set. Ranked by how much human evidence stands behind them, the gap between them and a growth-factor candidate is not subtle.
The classic nootropic classes carry decades of human exposure with defined dose ranges and known adverse effects, whereas the structural remodeling Dihexa was designed to produce has been observed only in cell culture and rodent models, and a small effect that is measured and characterized is a different kind of object from a large effect seen only in a dish.
The evidence gap is the single most important fact in any comparison of these compounds, and it is easy to state. What exists for Dihexa is a preclinical package concentrated in a small number of papers from the originating laboratory and its collaborators, and a large majority of compounds that reverse memory deficits in rodent models go on to fail in people.
As of the current published record there is no completed, peer-reviewed human clinical trial of Dihexa for any indication, while Cerebrolysin, Semax, Selank, piracetam, citicoline, donepezil and modafinil all carry at least some randomized controlled human data and the approved medicines among them carry full regulatory dossiers.
The safety comparison is not about which compound has the longer side effect list. For the established nootropics that list is short, dose-related and reversible: headache and irritability with racetams, gastrointestinal upset with cholinergic precursors, insomnia and raised heart rate with wakefulness agents, nausea and bradycardia with acetylcholinesterase inhibitors. The concern raised about Dihexa sits in a different category, because it comes from the mechanism itself rather than from an observed adverse event.
Dysregulated c-Met activation drives proliferation, invasion and metastasis in cancers of the lung, stomach, liver and kidney, and the tumor-promotion question raised by a compound designed to potentiate that pathway remains open only because the long-duration studies that would answer it have never been done, which makes the safety profile unknown rather than favorable.
Legal status splits these compounds into three tiers that casual discussion routinely blurs together, and Dihexa sits outside all three. The distinction is not academic: it determines whether any regulator has reviewed manufacturing, toxicology and trial data before a product reaches a person, and whether a lawful route to purchase exists at all.
Dihexa holds no marketing approval in any country, has never been through a new dietary ingredient notification and does not meet the definition of a dietary ingredient, so it cannot lawfully be sold for human consumption in the United States.
Delivery is the practical dividing line among these compounds and the reason several of them look inconvenient next to a capsule. Peptides taken by mouth are normally destroyed by gastric acid and intestinal proteases and absorb poorly, which is why Cerebrolysin is given by injection or infusion under supervision and why Semax and Selank are formulated as nasal drops that reach the brain by the olfactory route. The lipophilic caps on Dihexa were intended to sidestep that whole problem, and the evidence that they did comes from rodents.
| Compound group | Route reported | Human pharmacokinetics |
|---|---|---|
| Cerebrolysin | Intramuscular injection or intravenous infusion | Established clinical dosing in registering countries |
| Semax, Selank | Intranasal drops | Published dosing where registered |
| Racetams, citicoline, alpha-GPC, donepezil, modafinil | Oral | Established, with published half-lives |
| Dihexa | Oral activity reported in rodents | None; no human half-life measured |
Every established comparator has published human pharmacokinetics supporting a rational dosing schedule, while Dihexa's oral activity and brain penetration have been reported only in rodent studies, and rodent oral bioavailability is a poor predictor of the human figure, which has never been measured.
Price differences across these categories are real but far less consequential than what the price buys. A month of a generic acetylcholinesterase inhibitor or a supplement-grade cholinergic precursor is inexpensive and arrives through a supply chain that has been audited, while the research chemical market has no regulator checking either the certificate or the vial it is supposed to describe.
Pharmaceutical manufacture and the United States dietary supplement framework both carry enforceable identity, purity and manufacturing requirements, while nothing in the research chemical market ties price to verified quality, so an inexpensive vial may be accurately labeled and an expensive one may not.
Educational use only. This article describes what the published scientific and clinical literature reports about Dihexa and other cognition-focused nootropics. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
